Moral panic surrounding psychedelics

Moral panic surrounding psychedelics was a rapid reversal in public and professional attitudes: drugs that had recently attracted interest as possible treatments for mental illness and alcohol dependence came to be portrayed as threats to individual sanity and public order. The shift was neither a simple fabrication nor a measured response to evidence. Real emergencies and risks became entangled with sensational reporting, uncertain medical interpretation, and a political climate in which clinical research and uncontrolled street use were increasingly treated as one problem.

From therapeutic promise to public threat

In 1957, when R. Gordon Wasson’s account of a mushroom ceremony appeared in Life, psychedelics had not yet acquired the stigma that would define their public image a decade later. The magazine gave the story a large platform: its circulation was 5.7 million, and the feature introduced the phrase “magic mushrooms” to a mass readership. Wasson later appeared on the CBS program Person to Person, and other magazines published first-person accounts of mushroom journeys. He supplied mushrooms for ceremonies in his Manhattan apartment, while an exhibition followed at the American Museum of Natural History in New York. This early publicity presented psychedelic substances as a striking new subject of inquiry and experience, not yet as the emblem of a national crisis.

The reversal gathered force after quantities of illicit LSD appeared on the streets in 1962 and 1963. People experiencing acute distress began arriving in emergency rooms and psychiatric wards, and mainstream psychiatry increasingly abandoned research. In 1965, Bellevue Hospital in Manhattan admitted sixty-five people for what it classified as LSD-induced psychoses. In public discussion, the drug’s identity shifted from a possible treatment to an apparent cause of mental illness. The change was especially stark because it followed so soon after the enthusiastic attention given to Wasson’s story.

Genuine risks and uncertain diagnoses

The danger was not imaginary. During the mid-1960s, some people who had taken LSD experienced paranoia, mania, catatonia, anxiety, or recurring symptoms days or weeks later. Some had genuine psychotic breaks; the account notes that LSD could trigger a first episode in young people already at risk for schizophrenia. At the same time, physicians unfamiliar with psychedelic experiences sometimes interpreted panic reactions as psychosis, a response that could worsen the situation. The distinction between a frightening but temporary reaction and a severe psychiatric crisis was often difficult to make in the conditions created by sudden, widespread use.

Sidney Cohen’s research offers a measure of how the evidence changed and why sweeping conclusions were difficult. In a study begun in 1960, he surveyed forty-four researchers and gathered information on roughly five thousand people who had taken LSD or mescaline on a total of twenty-five thousand occasions. He found two credible reports of suicide, several temporary panic reactions, and no evidence of serious, prolonged physical side effects. His conclusion was conditional: complications were surprisingly infrequent when the drugs were administered by qualified therapists and researchers.

That finding did not settle the question. In a 1962 follow-up, Cohen warned that casual use outside clinical settings and use by irresponsible therapists were producing serious complications, including occasional catastrophic reactions. The following year he described psychotic breaks and an attempted suicide, as well as a boy who took LSD from a sugar cube confiscated by his detective father and experienced visual distortions and anxiety for more than a month before recovering. In 1966, Cohen reported two accidental deaths associated with LSD. His position therefore held two points together: risks had become serious in uncontrolled circumstances, while responsible therapeutic use still had potential. Public debate rarely preserved that distinction.

Headlines, rumor, and amplification

As fear intensified, reports and anecdotes accumulated into a general story of danger. Newspapers ran headlines linking LSD to deaths, mental damage, and an epidemic. Life, which had helped popularize psychedelic mushrooms nine years earlier, joined the denunciation with a cover story titled LSD: The Exploding Threat of the Mind Drug That Got out of Control. The cover story framed the drug as a danger that had escaped control, even though the magazine’s publisher and his wife had recently had positive LSD experiences under Sidney Cohen’s guidance. In this new framing, the salient distinction was no longer between supervised and unsupervised use; it was between the drug and the public presumed to be endangered by it.

Urban legends moved through the same channels as documented incidents, often more quickly than corrections. A widely publicized claim that six college students had gone blind after staring at the sun during an LSD trip was later traced to a hoax by Pennsylvania’s state commissioner for the blind. The correction received less attention than the original story. The episode also illustrates how rumors could acquire a second life: once a story had entered public consciousness, people on LSD could imitate it, making a previously false account seem to gain confirmation. The panic thus did more than magnify individual incidents; it helped shape the behavior and expectations through which later incidents were understood.

Research closes, distinctions collapse

The shift in public perception carried institutional consequences. In April 1966, Sandoz withdrew LSD-25 from circulation, hoping to distance itself from the controversy. It transferred most remaining stocks to the U.S. government, and many of the seventy research programs then under way shut down. At Senate hearings in May, Timothy Leary and Cohen tried to distinguish legitimate research from the black market. Senator Robert F. Kennedy questioned why projects considered worthwhile six months earlier should no longer be supported, and warned that a ban could deprive the country of a useful medicine. His appeal did not change the outcome.

In October, the FDA sent letters ordering some sixty researchers across the country to stop their work. James Fadiman received the notice at the International Foundation for Advanced Study in Menlo Park just after he had prepared four participants for a problem-solving session. The program closed the following day, along with virtually every other U.S. research program still operating. One major exception was the Maryland Psychiatric Research Center at Spring Grove, where researchers continued work on alcoholism, schizophrenia, and the existential distress of cancer patients until 1976.

The panic was therefore consequential not because every warning was false, but because complex differences—between clinical and casual use, panic and psychosis, or risk and certainty—became difficult to sustain in public and policy debate. The same media culture that had helped make psychedelic experience visible as a therapeutic and cultural possibility recast it as an uncontrolled threat. That change in framing accompanied the collapse of the first wave of psychedelic science.